Amgen (AMGN) Offering Possible 33.69% Return Over the Next 27 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $225.00 short put and a strike $215.00 long put offers a potential 33.69% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $225.00 by expiration. The full premium credit of $2.52 would be kept by the premium seller. The risk of $7.48 would be incurred if the stock dropped below the $215.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 61.76 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Amgen

Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral
Thu, 17 Dec 2020 21:10:00 +0000
Amgen (NASDAQ: AMGN) and LabCentral today announced that Octagon Therapeutics and Seranova Bio have each won an Amgen Golden Ticket to LabCentral, Cambridge's premier launchpad for high-potential life sciences and biotech start-ups. The two Golden Ticket winners were chosen by an internal team of Amgen scientific leaders and live audience members at a virtual pitch event on Dec. 9, 2020. Five finalists pitched their business plans to attendees where the audience members' votes served as input for the Amgen internal committee's decision.

FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Thu, 17 Dec 2020 21:00:00 +0000
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021.

Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
Thu, 17 Dec 2020 14:21:02 +0000
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut
Thu, 17 Dec 2020 13:10:19 +0000
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 16) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioLife Solutions Inc (NASDAQ: BLFS) * Castle Biosciences Inc (NASDAQ: CSTL) * Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) * Chimerix Inc (NASDAQ: CMRX) * Codexis, Inc. (NASDAQ: CDXS) * Corcept Therapeutics Incorporated (NASDAQ: CORT) * Eli Lilly And Co (NYSE: LLY) * Frequency Therapeutics Inc (NASDAQ: FREQ) * Globus Medical Inc (NYSE: GMED) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Inhibrx Inc (NASDAQ: INBX) * Medpace Holdings Inc (NASDAQ: MEDP) * Morphic Holding Inc (NASDAQ: MORF) * Nanobiotix ADR Representing Ord Shs (NASDAQ: NBTX) * NeoGenomics, Inc. (NASDAQ: NEO) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Otonomy Inc (NASDAQ: OTIC) * Revolution Medicines Inc (NASDAQ: RVMD) * Sesen Bio Inc (NASDAQ: SESN) * SI-Bone Inc (NASDAQ: SIBN) – announced that health insurer Humana Inc (NYSE: HUM) will begin to cover minimally invasive SI joint fusion using triangular titanium implants * Spero Therapeutics Inc (NASDAQ: SPRO) (announced addition to the Nasdaq Biotechnology Index) * Summit Therapeutics Inc (NASDAQ: SMMT) * TG Therapeutics Inc common stock (NASDAQ: TGTX) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * United Therapeutics Corporation (NASDAQ: UTHR) * Xencor Inc (NASDAQ: XNCR) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Zai Lab Ltd – ADR (NASDAQ: ZLAB)Down In The Dumps * (Biotech Stocks Hitting 52-week Lows Dec. 16) * AbCellera Biologics Inc (NASDAQ: ABCL) (listed on Friday following its IPO) * Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) -partner Gilead Sciences, Inc. (NASDAQ: GILD) said it is not pursuing approval of filgotinib in rheumatoid arthritis in the U.S. * Kinnate Biopharma Inc (NASDAQ: KNTE) * Olema Pharmaceuticals Inc (NASDAQ: OLMA) * Vivos Therapeutics Inc (NASDAQ: VVOS)Stocks In Focus MacroGenics Breast Cancer Drug Gets Regulatory Clearance, Commercialization Planned for March MacroGenics Inc (NASDAQ: MGNX) said the FDA has approved Margenza in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.Margenza is the first product approved from MacroGenics' pipeline, the company said. The company looks ahead to launch the product in March 2021.The stock was up 8.09% at $26.27 premarket Thursday. Mixed Verdict For Evolus In Botox Trade Secret Lawsuit Evolus Inc (NASDAQ: EOLS) said the U.S. International Trade Commission issued its final determination in the action brought by AbbVie Inc's (NYSE: ABBV) Allergan unit and Medytox against Daewoong and Evolus, reaffirming in part the initial determination of the administrative law judge finding a violation of Section 337 of the Tariff Act of 1930 as it relates to certain manufacturing processes.The ITC, however, reversed the ALJ's finding that a trade secret exists with respect to Medytox's bacterial strain. The commission issued orders preventing the import, sale and marketing of Jeuveau, a Botox rival, in the U.S. for 21 months, reducing it from the 10-year recommendation from the ALJ in July. Evolus said will now focus on overturning the decision by mobilizing interested parties close to this matter through the presidential review process, which will go on for a 60-day period.Evolus shares were up 16.89% premarket at $4.29.Amgen Submits Regulatory Application For Drug To Treat Lung Cancer With KRAS Mutation Amgen, Inc. (NASDAQ: AMGN) said it has submitted to the FDA an NDA for sotorasib, an investigational KRASG12C inhibitor for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, following at least one prior systemic therapy.”Sotorasib was the first KRASG12C inhibitor to enter the clinic and now is on track to potentially be the first approved targeted therapy for patients with advanced NSCLC harboring the KRAS G12C mutation,” the company said.Separately, the company announced a 10% hike to the quarterly dividend.The stock added 0.80% to $230.27 in after-hours trading.Zynerba To Conduct Pivotal Trial As Confirmatory Trial Required For Zygel Approval In Fragile X Syndrome Following a meeting with the FDA regarding its Zygel in fragile X syndrome, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) said it plans to conduct a double-blind, placebo-controlled pivotal trial in patients with FXS who have a highly methylated FMR1 gene to confirm the positive results observed in this population of responders in the CONNECT-FX trial. The company expects to initiate the pivotal trial before the end of 2021.Zynerba said it believes that positive results from this confirmatory trial would be sufficient to support the submission of an NDA for Zygel in FXS.Related Link: The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenicsAurinia Out-Licenses Rights To Kidney Inflammation Dug Outside The US To Japan's Otsuka Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) announced a collaboration and license agreement with Japan's Otsuka Pharmaceutical for the development and commercialization of oral voclosporin for the treatment of lupus nephritis in the European Union, Japan, as well as the U.K., Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.The agreement provides for Aurinia receiving an upfront cash payment of $50 million, and potentially up to an additional $50 million in regulatory and reimbursement milestone payments. Additionally, Aurinia will receive tiered royalties ranging from 10%-20% on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka.Voclosporin is currently being evaluated by the FDA, with a PDUFA action goal date of Jan. 22.Aurinia shares were slipping 2.77% to $14.75 in premarket trading Thursday.Selecta Biosciences Rallies On Insider Buying Selecta Biosciences Inc's (NASDAQ: SELB) chief commercial officer Peter Traber purchased 40,000 shares of the company at $3.2356 on Monday, according to a Form-4 filing by the company with the SEC.View more earnings on IBBThe stock was up 7.19% premarket at $3.13. Ziopharm Budges To Pressure By Activist Investor WaterMill, Appoints Rival Slate Of Directors; Chairman To Depart ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) said following the content solicitation by WaterMill Asset Management, Robert Postma Jaime Vieser and Holger Weis have been formally elected to its board.Chairman Scott Tarriff will depart the Board effective immediately, it added.On Monday, the company announced resignation of its CFO.In after-hours trading, the stock was up 5.07% to $2.90.Surface Oncology Out-Licenses Preclinical Asset To GlaxoSmithKline For Up To $815M Surface Oncology Inc (NASDAQ: SURF) announced an agreement for GlaxoSmithKline plc (NYSE: GSK) to exclusively license worldwide development and commercial rights to its preclinical program SRF813, an inhibitory protein expressed on natural killer cells and T cells, for an $85-million upfront payment.Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales.Surface Oncology shares were trading up 3.11% to $10.27, while GlaxoSmithKline was adding 2.39% to $37.76. Otonomy Reports Positive Phase 1/2 Study Of OTO-413 For Hearing Loss Otonomy announced positive top-line results from the Phase 1/2 clinical trial of OTO-413 in subjects with speech-in-noise hearing difficulty, with the investigational asset found to be well-tolerated across all dose cohorts.Furthermore, there was demonstration of therapeutic activity of OTO-413 versus placebo across multiple clinically validated speech-in-noise hearing tests at consecutive time points (days 57 and 85), the company said. Based on these results, the company said it plans to continue development of OTO-413 for the treatment of hearing loss.Otonomy shares were rallying 4.13% to $5.80 premarket Thursday. Offerings SCYNEXIS Inc (NASDAQ: SCYX) said it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. All of the securities are being sold by the company.The stock was down 18.14% premarket at $6. Gamida Cell Ltd (NASDAQ: GMDA) announced the launch of a follow-on public offering of its ordinary shares. All of the shares in the offering are to be sold by Gamida Cell.On The Radar Adcom Review Moderna (NASDAQ: MRNA) will face the FDA's Center for Biologics Evaluation and Research's Vaccines and Related Biological Products Advisory Committee on Dec. 17 regarding the EUA application it has filed for its coronavirus vaccine candidate mRNA-1273.Moderna's shares have fully discounted near-term COVID-19 vaccine revenue, Morgan Stanley's Matthew Harrison said in a note Wednesday.Clinical Readouts BioCardia Inc (NASDAQ: BCDA) said it will provide ahead of the market open an update on the feedback from the data safety monitoring board, which evaluated the interim data from its pivotal Phase 3 CardiAMP Heart Failure Trial that is enrolling nationwide for infusion of BioCardia's CardiAMP autologous cell therapy to the myocardium.MeiraGTx Holdings PLC (NASDAQ: MGTX) is scheduled to discuss the first cohort of three patients treated in the Phase 1 AQUAx clinical trial that is evaluating its investigational gene therapy AAV-hAQP1 in radiation-induced xerostomia.Earnings Applied DNA Sciences Inc (NASDAQ: APDN) (after the close)IPOs Virios therapeutics, a biotech focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, priced its initial public offering of 3 million shares of its common stock at $10 per share, for gross proceeds of $30 million.The shares are expected to begin trading on the Nasdaq under the ticker symbol “VIRI.” The offering is expected to close on Dec. 21.Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal * The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3 Dividend Stocks That Have Doubled Their Payouts in 5 Years
Thu, 17 Dec 2020 11:17:00 +0000
Three stocks that have been growing their payouts at a much more rapid pace include Amgen (NASDAQ: AMGN), Visa (NYSE: V), and The Home Depot (NYSE: HD). Healthcare company Amgen is a great dividend stock because its profits are consistent and it has a lot of financial wiggle room to make sure that its payouts can continue. In each of the past eight quarterly results, Amgen's net profit margin has come in higher than 27%.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.